Pfizer’s Pegfilgrastim Biosimilar ‘Has Launched’ In The US
FDA Approval In June 2020 Hung Up By IP Barriers
Pfizer has pressed on with the launch of a fourth biosimilar pegfilgrastim product, Nyvepria (pegfilgrastim-apgf), according to an investment bank. With Amgen continuing to hold more than 70% of the market, there is opportunity for Pfizer to capture significant market share.
You may also be interested in...
Pfizer’s US biosimilars sales approached $1bn last year, following a number of launches and continued uptake for key products, while revenues in international markets, especially Europe, also increased.
Pfizer has revealed launch plans for its Nyvepria pegfilgrastim biosimilar, shortly after receiving formal European Commission approval.
Pfizer has won the first US Food and Drug Administration biosimilar approval this year, for its Nyvepria (pegfilgrastim-apgf) pre-filled syringes. However, it must overcome intellectual property hurdles before it can roll out the product.